Newsroom

Download PDF CAMBRIDGE, MA, June 18, 2007– AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded the Ernst & Young New England Entrepreneur of the Year® in the life sciences

Download PDF Cambridge, MA – May 3, 2007 – AVEO Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced that it has closed a $53 million Series D financing.  Proceeds from this financing will be used to accelerate the development of AVEO’s pipeline of novel, clinical-stage cancer

Download PDF – AVEO Pharmaceuticals Success with Breast Cancer Mouse Model Presented Today at AACR – LOS ANGELES CAMBRIDGE, Mass.–April 18, 2007–AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from its novel human-in-mouse (HIM) tissue transgenic cancer model system, in which AVEO successfully

Download PDF Data Presented at the American Association for Cancer Research (AACR) Annual Meeting LOS ANGELES, CA, and CAMBRIDGE, MA, April 17, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced encouraging preclinical data of AV-412, a novel, next generation oral tyrosine kinase

Download PDF – Data to be Featured in Five Oral Presentations and Seven Poster Sessions – CAMBRIDGE, MA April 12, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, announced today that it will present a total of 12 oral and poster presentations at the

Download PDF – Company to Participate in Development and Commercialization – CAMBRIDGE, MA April 4, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299.  AV-299, an antibody discovered

Download PDF AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio CAMBRIDGE, Mass. Jan. 04, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has acquired from Kirin Brewery Co., Ltd. an exclusive license to develop and commercialize Kirin’s highly potent

Download PDF CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase inhibitor of EGFR/HER2.  The open-label, sequential dose escalation study